The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Makogon N.V.

National Medical Research Center for Therapy and Preventive Medicine

Chashchin M.G.

National Medical Research Center for Therapy and Preventive Medicine

Kontsevaya A.V.

National Medical Research Center for Therapy and Preventive Medicine

Shalnova S.A.

National Medical Research Center for Therapy and Preventive Medicine

Drapkina O.M.

National Medical Research Center for Therapy and Preventive Medicine

Troponin I as a marker of cardiovascular risk: pathophysiological mechanisms and data from population studies

Authors:

Makogon N.V., Chashchin M.G., Kontsevaya A.V., Shalnova S.A., Drapkina O.M.

More about the authors

Journal: Russian Journal of Cardiology and Cardiovascular Surgery. 2025;18(6): 685‑692

DOI: 10.17116/kardio202518061685

Read: 513 times

Buy for 300₽
Contact the author
Table of contents

TROPONIN I AS A MARKER OF CARDIOVASCULAR RISK: PATHOPHYSIOLOGICAL MECHANISMS AND DATA FROM POPULATION STUDIES
TROPONIN I AS A MARKER OF CARDIOVASCULAR RISK: PATHOPHYSIOLOGICAL MECHANISMS AND DATA FROM POPULATION STUDIES

To cite this article:

Makogon NV, Chashchin MG, Kontsevaya AV, Shalnova SA, Drapkina OM. Troponin I as a marker of cardiovascular risk: pathophysiological mechanisms and data from population studies. Russian Journal of Cardiology and Cardiovascular Surgery. 2025;18(6):685‑692. (In Russ.)
https://doi.org/10.17116/kardio202518061685

Подписка 2026 Кардиология и сердечно-сосудистая хирургия (Russian Journal of Cardiology and Cardiovascular Surgery)
МСФ на ЯМ
Использование инфографики авторами научных работ
Recommended articles:
QRISK-3 cardiovascular risk asse­ssment algo­rithm in prediction of kidney transplantation outcomes. Russian Cardiology Bulletin. 2025;(2):61-69
Triglycerides-Glucose Index as an inte­gral biomarker of insu­lin resi­stance and cardiovascular diseases. Russian Journal of Preventive Medi­cine. 2025;(5):124-129
Contribution of the Russian Academy of Sciences Academician R.G. Oganov to the deve­lopment of the dome­stic preventive cardiology. Russian Journal of Preventive Medi­cine. 2025;(6):7-10
Hype­rtensive diso­rders of pregnancy as a risk factor for chro­nic non-communicable diseases. Russian Journal of Preventive Medi­cine. 2025;(6):114-119
Features of care of patients with cardiovascular diseases and cognitive diso­rders. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(6):99-104
Myokines — the cardiometabolic risk pote­ntial biomarkers. Russian Journal of Preventive Medi­cine. 2025;(7):119-126
The Webiomed.DHRA deci­sion-making support system for medi­cal examinations in the Russian Fede­ration: a cost-effectiveness analysis. Medi­cal Technologies. Asse­ssment and Choice. 2025;(3):61-73
Study of the effe­ctiveness of the drug Elca­rnitine in the correction of increased variability of arte­rial pressure in patients with hype­rtensive disease and cognitive dysfunction. Russian Journal of Preventive Medi­cine. 2025;(10):88-92
Multimorbidity, risk factors and causes of death in patients with cardiovascular diseases during long-term posthospital moni­toring. Russian Journal of Preventive Medi­cine. 2025;(11):36-44
Gender features of the vascular wall condition in young people with the body weight excess. Russian Journal of Preventive Medi­cine. 2025;(11):52-58
Abstract:

Cardiovascular diseases remain the leading cause of death worldwide, so there is a great need for novel biomarkers that will identify individuals with high risk of cardiovascular events. One of the most promising markers in predicting cardiovascular outcomes is cardiac troponin I. The purpose of this review is to summarize recent data on pathophysiological mechanisms of troponin I release, gender, age and ethnic characteristics of basal level of troponin I, as well as prospects of troponin I for stratification of individual cardiovascular risk.

Keywords:

troponin I
risk marker
cardiovascular risk
population studies
cardiovascular diseases

Authors:

Makogon N.V.

National Medical Research Center for Therapy and Preventive Medicine

Chashchin M.G.

National Medical Research Center for Therapy and Preventive Medicine

Kontsevaya A.V.

National Medical Research Center for Therapy and Preventive Medicine

Shalnova S.A.

National Medical Research Center for Therapy and Preventive Medicine

Drapkina O.M.

National Medical Research Center for Therapy and Preventive Medicine

Received:

05.11.2024

Accepted:

19.12.2024

Close metadata

References:

  1. Ss V, A A, Ej B, et al. Heart Disease and Stroke Statistics-2020 Update: A Report From the American Heart Association. Circulation. 2020;141(9). https://doi.org/10.1161/CIR.0000000000000757
  2. Oganov RG, Kontsevaya AV, Kalinina AM. Economic burden of cardiovascular disease in the Russian Federation. Cardiovascular Therapy and Prevention. 2011;10(4):4-9. (In Russ.). https://doi.org/10.15829/1728-8800-2011-4-4-9
  3. Shlyakhto EV, Zvartau NE, Villevalde SV, et al. Cardiovascular risk management system: prerequisites for developing, organization principles, target groups. Russ J Cardiol. 2019;0(11):69-82 (In Russ.). https://doi.org/10.15829/1560-4071-2019-11-69-82
  4. https://rosstat.gov.ru/storage/mediabank/Ejegodnik_2021.pdf  EF.Baranov,TS.Bezborodova,SN.Bobylev,etal.Russianstatisticalyearbook.FederalStateStatisticsService;2021(InRuss.).
  5. Kontsevaya AN, Drapkina OM, Balanova YA, et al. Economic burden of cardiovascular diseases in the russian federation in 2016. Ration Pharmacother Cardiol. 2018;14(2):156-166. (In Russ.). https://doi.org/10.20996/1819-6446-2018-14-2-156-166
  6. Skopets IS, Vesikova NN, Bershtein LL. High risk strategy efficacy in prognosis of primary onset of ischemic heart. Cardiovascular Therapy and Prevention. 2014;13(6):38-43. (In Russ.). https://doi.org/10.15829/1728-8800-2014-6-38-43
  7. Smith ER. Risk prediction in cardiovascular disease--current status and future challenges. Can J Cardiol. 2009;25 Suppl A(Suppl A):7A.  https://doi.org/10.1016/s0828-282x(09)71047-5
  8. Farzadfar F. Cardiovascular disease risk prediction models: challenges and perspectives. Lancet Glob Health. 2019;7(10):e1288-e1289. https://doi.org/10.1016/S2214-109X(19)30365-1
  9. Grauman Å, Veldwijk J, James S, et al. Good general health and lack of family history influence the underestimation of cardiovascular risk: a cross-sectional study. Eur J Cardiovasc Nurs. 2021;20(7):676-683.  https://doi.org/10.1093/eurjcn/zvab019
  10. Drapkina OM, Shalnova SA, Kontsevaya AV, et al. Prognostic significance of troponin I in assessing cardiovascular risk in the Russian population. Data from ESSE-RF1 and ESSE-RF2 multicenter studies. Cardiovascular Therapy and Prevention. 2023;22(5):3548. (In Russ.). https://doi.org/10.15829/1728-8800-2023-3548
  11. Katrukha IA. Human cardiac troponin complex. Structure and functions. Biochem Biokhimiia. 2013;78(13):1447-1465. https://doi.org/10.1134/S0006297913130063
  12. Sasse S, Brand NJ, Kyprianou P, et al. Troponin I gene expression during human cardiac development and in end-stage heart failure. Circ Res. 1993;72(5):932-938.  https://doi.org/10.1161/01.res.72.5.932
  13. Wens SCA, Schaaf GJ, Michels M, et al. Elevated Plasma Cardiac Troponin T Levels Caused by Skeletal Muscle Damage in Pompe Disease. Circ Cardiovasc Genet. 2016;9(1):6-13.  https://doi.org/10.1161/CIRCGENETICS.115.001322
  14. Jaffe AS, Vasile VC, Milone M, et al. Diseased skeletal muscle: a noncardiac source of increased circulating concentrations of cardiac troponin T. J Am Coll Cardiol. 2011;58(17):1819-1824. https://doi.org/10.1016/j.jacc.2011.08.026
  15. Rusakov DYu, Vologdina NN, Tulayeva ON. The development of striated cardiac muscle tissue in the walls of the caval and pulmonary veins. Journal of Anatomy and Histopathology. 2015;4(3):105-105. (In Russ.).
  16. Messner B, Baum H, Fischer P, et al. Expression of messenger RNA of the cardiac isoforms of troponin T and I in myopathic skeletal muscle. Am J Clin Pathol. 2000;114(4):544-549. 
  17. Starnberg K, Fridén V, Muslimovic A, et al. A Possible Mechanism behind Faster Clearance and Higher Peak Concentrations of Cardiac Troponin I Compared with Troponin T in Acute Myocardial Infarction. Clin Chem. 2020;66(2):333-341.  https://doi.org/10.1093/clinchem/hvz003
  18. Thygesen K, Alpert JS, Jaffe AS, et al. Fourth Universal Definition of Myocardial Infarction (2018). Circulation. 2018;138(20):e618-e651. https://doi.org/10.1161/CIR.0000000000000617
  19. Zhu K, Knuiman M, Divitini M, et al. High-sensitivity cardiac troponin I and risk of cardiovascular disease in an Australianpopulation-based cohort. Heart Br Card Soc. 2018;104(11):895-903.  https://doi.org/10.1136/heartjnl-2017-312093
  20. Tang O, Matsushita K, Coresh J, et al. High-Sensitivity Cardiac Troponin I for Risk Stratification in Older Adults. J Am Geriatr Soc. 2021;69(4):986-994.  https://doi.org/10.1111/jgs.16912
  21. Jia X, Sun W, Hoogeveen RC, et al. High-Sensitivity Troponin I and Incident Coronary Events, Stroke, Heart Failure Hospitalization, and Mortality in the ARIC Study. Circulation. 2019;139(23):2642-2653. https://doi.org/10.1161/CIRCULATIONAHA.118.038772
  22. White HD. Pathobiology of troponin elevations: do elevations occur with myocardial ischemia as well as necrosis? J Am Coll Cardiol. 2011;57(24):2406-2408. https://doi.org/10.1016/j.jacc.2011.01.029
  23. Heusch G. Myocardial stunning and hibernation revisited. Nat Rev Cardiol. 2021;18(7):522-536.  https://doi.org/10.1038/s41569-021-00506-7
  24. Weil BR, Young RF, Shen X, et al. Brief Myocardial Ischemia Produces Cardiac Troponin I Release and Focal Myocyte Apoptosis in the Absence of Pathological Infarction in Swine. JACC Basic Transl Sci. 2017;2(2):105-114.  https://doi.org/10.1016/j.jacbts.2017.01.006
  25. Yao L, Chen H, Wu Q, Xie K. Hydrogen-rich saline alleviates inflammation and apoptosis in myocardial I/R injury via PINK-mediated autophagy. Int J Mol Med. 2019;44(3):1048-1062. https://doi.org/10.3892/ijmm.2019.4264
  26. Árnadóttir Á, Pedersen S, Bo Hasselbalch R, et al. Temporal Release of High-Sensitivity Cardiac Troponin T and I and Copeptin After Brief Induced Coronary Artery Balloon Occlusion in Humans. Circulation. 2021;143(11):1095-1104. https://doi.org/10.1161/CIRCULATIONAHA.120.046574
  27. Chenevier-Gobeaux C, Bonnefoy-Cudraz É, Charpentier S, et al. High-sensitivity cardiac troponin assays: answers to frequently asked questions. Arch Cardiovasc Dis. 2015;108(2):132-149.  https://doi.org/10.1016/j.acvd.2014.11.001
  28. Bergmann O, Jovinge S. Cardiac regeneration in vivo: mending the heart from within? Stem Cell Res. 2014;13(3 Pt B):523-531.  https://doi.org/10.1016/j.scr.2014.07.002
  29. Mollova M, Bersell K, Walsh S, et al. Cardiomyocyte proliferation contributes to heart growth in young humans. Proc Natl Acad Sci U S A. 2013;110(4):1446-1451. https://doi.org/10.1073/pnas.1214608110
  30. Shafique S, Ali SR, Rajput SN, et al. Cardiac Transcription Regulators Differentiate Human Umbilical Cord Mesenchymal Stem Cells into Cardiac Cells. Altern Lab Anim ATLA. 2023;51(1):12-29.  https://doi.org/10.1177/02611929221143774
  31. Potter JM, Hickman PE, Cullen L. Troponins in myocardial infarction and injury. Aust Prescr. 2022;45(2):53-57.  https://doi.org/10.18773/austprescr.2022.006
  32. Ross RS, Borg TK. Integrins and the myocardium. Circ Res. 2001;88(11):1112-1119. https://doi.org/10.1161/hh1101.091862
  33. Hessel MH, Atsma DE, van der Valk EJ, et al. Release of cardiac troponin I from viable cardiomyocytes is mediated by integrin stimulation. Pflugers Arch. 2008;455(6):979-986.  https://doi.org/10.1007/s00424-007-0354-8
  34. Gu SR, Kang YG, Shin JW, Shin JW. Simultaneous engagement of mechanical stretching and surface pattern promotes cardiomyogenic differentiation of human mesenchymal stem cells. J Biosci Bioeng. 2017;123(2):252-258.  https://doi.org/10.1016/j.jbiosc.2016.07.020
  35. Weil BR, Suzuki G, Young RF, et al. Troponin Release and Reversible Left Ventricular Dysfunction After Transient Pressure Overload. J Am Coll Cardiol. 2018;71(25):2906-2916. https://doi.org/10.1016/j.jacc.2018.04.029
  36. Zainudin H, Caszo BA, Knight VF, Gnanou JV. Training Induced Oxidative Stress-Derived DNA and Muscle Damage in Triathletes. Eurasian J Med. 2019;51(2):116-120.  https://doi.org/10.5152/eurasianjmed.2019.18106
  37. Madsen LH, Christensen G, Lund T, et al. Time course of degradation of cardiac troponin I in patients with acute ST-elevation myocardial infarction: the ASSENT-2 troponin substudy. Circ Res. 2006;99(10):1141-1147. https://doi.org/10.1161/01.RES.0000249531.23654.e1
  38. Feng J, Schaus BJ, Fallavollita JA, et. al. Preload induces troponin I degradation independently of myocardial ischemia. Circulation. 2001;103(16):2035-2037. https://doi.org/10.1161/01.cir.103.16.2035
  39. Nicolás-Ávila JA, Lechuga-Vieco AV, Esteban-Martínez L, et al. A Network of Macrophages Supports Mitochondrial Homeostasis in the Heart. Cell. 2020;183(1):94-109.e23.  https://doi.org/10.1016/j.cell.2020.08.031
  40. Kimenai DM, Janssen EBNJ, Eggers KM, et al. Sex-Specific Versus Overall Clinical Decision Limits for Cardiac Troponin I and T for the Diagnosis of Acute Myocardial Infarction: A Systematic Review. Clin Chem. 2018;64(7):1034-1043. https://doi.org/10.1373/clinchem.2018.286781
  41. Apple FS, Sandoval Y, Jaffe AS, Ordonez-Llanos J, IFCC Task Force on Clinical Applications of Cardiac Bio-Markers. Cardiac Troponin Assays: Guide to Understanding Analytical Characteristics and Their Impact on Clinical Care. Clin Chem. 2017;63(1):73-81.  https://doi.org/10.1373/clinchem.2016.255109
  42. de Bakker M, Anand A, Shipley M, et al. Sex Differences in Cardiac Troponin Trajectories Over the Life Course. Circulation. 2023;147(24):1798-1808. https://doi.org/10.1161/CIRCULATIONAHA.123.064386
  43. Bergström G, Persson M, Adiels M, et al. Prevalence of Subclinical Coronary Artery Atherosclerosis in the General Population. Circulation. 2021;144(12):916-929.  https://doi.org/10.1161/CIRCULATIONAHA.121.055340
  44. He B, Wang K, Xu P, et al. Determination of Age- and Sex-Specific 99th Percentile Upper Reference Limits for High-Sensitivity Cardiac Troponin I in Healthy Chinese Adults. Cardiology. 2022;147(3):261-270.  https://doi.org/10.1159/000523721
  45. Riffel JH, Mayo R, Mueller-Hennessen M, et al. Age- and gender-related reference values of cardiac morphology and function in cardiovascular magnetic resonance. Int J Cardiovasc Imaging. 2021;37(6):2011-2023. https://doi.org/10.1007/s10554-021-02160-z
  46. Yeon SB, Salton CJ, Gona P, et al. Impact of age, sex, and indexation method on MR left ventricular reference values in the Framingham Heart Study offspring cohort. J Magn Reson Imaging JMRI. 2015;41(4):1038-1045. https://doi.org/10.1002/jmri.24649
  47. de Simone G, Devereux RB, Daniels SR, Meyer RA. Gender differences in left ventricular growth. Hypertens Dallas Tex 1979. 1995;26(6 Pt 1):979-983.  https://doi.org/10.1161/01.hyp.26.6.979
  48. Yerly A, van der Vorst EPC, Baumgartner I, et al. Sex-specific and hormone-related differences in vascular remodelling in atherosclerosis. Eur J Clin Invest. 2023;53(1):e13885. https://doi.org/10.1111/eci.13885
  49. Subramanya V, Zhao D, Ouyang P, et al. Sex Hormone Levels and Change in Left Ventricular Structure Among Men and Post-Menopausal Women: The Multi-Ethnic Study of Atherosclerosis (MESA). Maturitas. 2018;108:37-44.  https://doi.org/10.1016/j.maturitas.2017.11.006
  50. Kalaria TR, Harris N, Sensi H, et al. High-sensitivity cardiac troponin I: is ethnicity relevant? J Clin Pathol. 2021;74(11):709-711.  https://doi.org/10.1136/jclinpath-2020-206951
  51. Iribarren C, Chandra M, Rana JS, et al. High-sensitivity cardiac troponin I and incident coronary heart disease among asymptomatic older adults. Heart. 2016;102(15):1177-1182. https://doi.org/10.1136/heartjnl-2015-309136
  52. Gijsberts CM, Seneviratna A, Bank IEM, et al. The ethnicity-specific association of biomarkers with the angiographic severity of coronary artery disease. Neth Heart J. 2016;24(3):188-198.  https://doi.org/10.1007/s12471-015-0798-y
  53. Liu C, Deng Z, Wu W, et al. Ethnicity and sex-specific 99th percentile upper reference limits of high-sensitivity cardiac troponin I among adults in Xinjiang, China. Clin Biochem. 2023;116:94-99.  https://doi.org/10.1016/j.clinbiochem.2023.04.004
  54. Shao J, Li Y, Xia J, et al. Trends in ethnic disparities in clinical cardiovascular health among Chinese adults from 2016-2020. Nutr Metab Cardiovasc Dis. 2023;33(4):749-757.  https://doi.org/10.1016/j.numecd.2023.01.006
  55. Kontsevaya AV, Myrzamatova A AO, Polupanov AG, Alikhanova KA, Kashirin AK, Khalmatov AN, Altymysheva AT, Iskakov EB, Balanova YuA, Dzhumagulova AS. Ethnic specifics of the main cardiovascular risk factors prevalence among rural inhabitants of a russian region and regions of kyrgyzstan and kazakhstan. Russian Journal of Cardiology. 2017;(6):113-121. (In Russ.). https://doi.org/10.15829/1560-4071-2017-6-113-121
  56. Lind L, Sundström J, Ärnlöv J, Lampa E. Impact of Aging on the Strength of Cardiovascular Risk Factors: A Longitudinal Study Over 40 Years. J Am Heart Assoc. 2018;7(1):e007061. https://doi.org/10.1161/JAHA.117.007061
  57. Empana JP, Lerner I, Perier MC, et al. Ultrasensitive Troponin I and Incident Cardiovascular Disease. Arterioscler Thromb Vasc Biol. 2022;42(12):1471-1481. https://doi.org/10.1161/ATVBAHA.122.317961
  58. Sigurdardottir FD, Lyngbakken MN, Holmen OL, et al. Relative Prognostic Value of Cardiac Troponin I and C-Reactive Protein in the General Population (from the Nord-Trøndelag Health HUNT] Study). Am J Cardiol. 2018;121(8):949-955.  https://doi.org/10.1016/j.amjcard.2018.01.004
  59. Wong ND, Zhao Y, Quek RGW, et al. Residual Atherosclerotic Cardiovascular Disease Risk in Statin-Treated Adults: The Multi-Ethnic Study of Atherosclerosis. J Clin Lipidol. 2017;11(5):1223-1233. https://doi.org/10.1016/j.jacl.2017.06.015
  60. Jülicher P, Varounis C. Estimating the cost-effectiveness of screening a general population for cardiovascular risk with high-sensitivity troponin-I. Eur Heart J Qual Care Clin Outcomes. 2021;8(3):342-351.  https://doi.org/10.1093/ehjqcco/qcab005
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.